See What HealthDay Can Do For You
Contact Us

H2 Injection Aids Diabetes Outcomes in Animal Model

Subcutaneous injection may be an effective means of administration


WEDNESDAY, May 3, 2017 (HealthDay News) -- Subcutaneous injection of H2 significantly improves type 2 diabetes mellitus (T2DM)-related outcomes in a mouse model, according to a study published online April 8 in the Journal of Diabetes Investigation.

Xiaolong Zhang, from the Second Affiliated Hospital of Wenzhou Medical University in China, and colleagues evaluated whether subcutaneous injection of H2 (1 mL/mouse/week for four weeks) shows enhanced efficacy against T2DM induced in mice by a high-fat diet and low-dose streptozotocin treatment.

The researchers found that the body weight of H2-treated mice did not change over the study period. Glucose, insulin, low-density lipoprotein, and triglyceride levels in serum were significantly lower in treated mice versus untreated controls, while high-density lipoprotein cholesterol in the serum was significantly higher. In H2-treated mice, both glucose tolerance and insulin sensitivity were improved. H2 treatment also lead to significant reductions in urine volume, urinary total protein and β2 microglobulin, kidney/body weight ratio, and kidney fibrosis, in diabetic nephropathy analysis.

"Subcutaneous injection of H2 significantly improves T2DM and diabetic nephropathy related outcomes in a mouse model, supporting further consideration of subcutaneous injection as a novel and effective route of clinical H2 administration," the authors write.

Full Text

Physician's Briefing